Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ionis Pharmaceuticals (IONS), FibroGen (FGEN) and NGM Biopharmaceuticals (NGM).
Ionis Pharmaceuticals (IONS)
William Blair analyst Myles Minter reiterated a Hold rating on Ionis Pharmaceuticals on September 2. The company’s shares closed last Friday at $55.30.
According to TipRanks.com, Minter is a 4-star analyst with an average return of 20.7% and a 34.8% success rate. Minter covers the Healthcare sector, focusing on stocks such as Minerva Neurosciences, Axsome Therapeutics, and Karuna Therapeutics.
Ionis Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $72.75, a 31.2% upside from current levels. In a report issued on September 2, Benchmark Co. also initiated coverage with a Hold rating on the stock.
See today’s analyst top recommended stocks >>
FibroGen (FGEN)
William Blair analyst Andy Hsieh reiterated a Hold rating on FibroGen yesterday. The company’s shares closed last Friday at $43.11.
According to TipRanks.com, Hsieh is a 4-star analyst with an average return of 13.7% and a 56.5% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Seattle Genetics, and Beyondspring.
Currently, the analyst consensus on FibroGen is a Strong Buy with an average price target of $75.67.
NGM Biopharmaceuticals (NGM)
In a report released today, Mayank Mamtani from B.Riley FBR maintained a Buy rating on NGM Biopharmaceuticals, with a price target of $30.00. The company’s shares closed last Friday at $17.42.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 16.4% and a 44.8% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals.
NGM Biopharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $31.25, which is a 77.2% upside from current levels. In a report issued on August 30, Piper Sandler also maintained a Buy rating on the stock with a $30.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
